Reply

Affiliations

¹ Department of Ophthalmology, University of Bonn, Bonn, Germany.
² Department of Ophthalmology, Ramon y Cajal University Hospital, Madrid, Spain.
³ Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy.
⁴ Department of Ophthalmology, Wolverhampton Eye Infirmary, Wolverhampton, United Kingdom.
⁵ Department of Ophthalmology, School of Health and Life Sciences, Aston University, Birmingham, United Kingdom.
⁶ Department of Ophthalmology, Shiga University of Medical Science, Otsu, Shiga, Japan.
⁷ Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Beijing, China.
⁸ Department of Ophthalmology, I Kliniki Okulistyki Slaskiej Akademii Medycznej w Katowicach, Katowice, Poland.
⁹ Department of Ophthalmology and Epidemiology, Queen's University, Kingston, Ontario, Canada.
¹⁰ Department of Ophthalmology, Novartis Pharma AG, Basel, Switzerland.
¹¹ Department of Ophthalmology, Novartis Pharmaceuticals UK Limited, Surrey, Frimley, Camberley, United Kingdom.
¹² Department of Ophthalmology, Centre for Vision Research, Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.

Comment

Frank G Holz et al. Retina. 2020 Sep.

. 2020 Sep;40(9):e51-e53.

doi: 10.1097/IAE.0000000000002909.

¹ Department of Ophthalmology, University of Bonn, Bonn, Germany.
² Department of Ophthalmology, Ramon y Cajal University Hospital, Madrid, Spain.
³ Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy.
⁴ Department of Ophthalmology, Wolverhampton Eye Infirmary, Wolverhampton, United Kingdom.
⁵ Department of Ophthalmology, School of Health and Life Sciences, Aston University, Birmingham, United Kingdom.
⁶ Department of Ophthalmology, Shiga University of Medical Science, Otsu, Shiga, Japan.
⁷ Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Beijing, China.
⁸ Department of Ophthalmology, I Kliniki Okulistyki Slaskiej Akademii Medycznej w Katowicach, Katowice, Poland.
⁹ Department of Ophthalmology and Epidemiology, Queen's University, Kingston, Ontario, Canada.
¹⁰ Department of Ophthalmology, Novartis Pharma AG, Basel, Switzerland.
¹¹ Department of Ophthalmology, Novartis Pharmaceuticals UK Limited, Surrey, Frimley, Camberley, United Kingdom.
¹² Department of Ophthalmology, Centre for Vision Research, Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.

No abstract available

Comment on

RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study.
Holz FG, Figueroa MS, Bandello F, Yang Y, Ohji M, Dai H, Wykrota H, Sharma S, Dunger-Baldauf C, Lacey S, Macfadden W, Mitchell P; all the LUMINOUS study investigators. Holz FG, et al. Retina. 2020 Sep;40(9):1673-1685. doi: 10.1097/IAE.0000000000002670. Retina. 2020. PMID: 31764612 Free PMC article.
Correspondence.
Călugăru D, Călugăru M. Călugăru D, et al. Retina. 2020 Sep;40(9):e49-e51. doi: 10.1097/IAE.0000000000002908. Retina. 2020. PMID: 32842091 No abstract available.

1. Holz FG, Figueroa MS, Bandello F, et al. Ranibizumab treatment in treatment-naïve neovascular age-related macular degeneration: results from LUMINOUS, a global, real-world study. Retina 2019. doi: 10.1097/IAE.0000000000002670 [Epub ahead of print]. - DOI
1. Lucentis Summary of Product Characteristics 2011. Available at: https://www.ema.europa.eu/en/documents/product-information/lucentis-epar.... Accessed April 30, 2020.